

***Drug Screening using Shape-based Virtual Screening and In Vitro  
Experimental Models of Cutaneous Leishmaniasis***

C. C. Santos<sup>1</sup>; M. M. Batista<sup>1</sup>, Asma Inam Ullah<sup>2</sup>, Tummala Rama Krishna Reddy<sup>2</sup>  
and Maria de Nazaré C. Soeiro<sup>1\*</sup>

<sup>1</sup>Laboratory of Cellular Biology (LBC), Oswaldo Cruz Institute (IOC/FIOCRUZ),  
CEP21040-360 Rio de Janeiro, RJ, Brasil.

<sup>2</sup> The Medicines Research Group, School of Health, Sport and Bioscience, College  
of Applied Health and Communities, University of East London, Stratford campus,  
Water Lane, UK.

\*Corresponding author. Tel: +55-21-25621368; e-mail: soeiro@ioc.fiocruz.br

**RUNNING TITLE:** Leishmanicidal activity of Oxazolo[4,5-b] pyridine derivative  
and benzimidazole derivative.

## Synopsis

Cutaneous leishmaniasis (CL) is one of the most disregarded tropical neglected disease with the occurrence of self-limiting ulcers and triggering mucosal damage and stigmatizing scars, leading to huge public health problems and social negative impacts. Pentavalent antimonials are the first-line drug for CL treatment for over 70 years and present several drawbacks in terms of safety and efficacy. Thus, there is an urgent need to search for non-invasive, non-toxic, and potent drug candidates for CL. In this sense, we have implemented a shape-based virtual screening approach and identified a set of 32 hit compounds. *In vitro* phenotypic screenings were conducted using these hit compounds to check their potential leishmanicidal effect towards *Leishmania amazonensis*. The findings showed that two (Cp1 and Cp2) out of the 32 compounds revealed promising antiparasitic activities, exhibiting considerable potency against intracellular amastigotes present in peritoneal macrophages (IC<sub>50</sub> values of 9.35 and 7.25  $\mu$ M, respectively). Also, a sterile cidal profile was reached at 20  $\mu$ M after 48 hours of incubation, besides a reasonable selectivity ( $\approx 8$ ), quite similarly to pentamidine, an aromatic diamidine still in use clinically for leishmaniasis. Cp1 with an Oxazolo[4,5-b]pyridine scaffold and Cp2 with a benzimidazole scaffold could be developed further by lead optimization studies to enhance their leishmanicidal potency.

**KEY WORDS:** Cutaneous leishmaniasis, *Leishmania amazonensis*, shape-based virtual screening, *in vitro* experimental chemotherapy.

## Introduction

Cutaneous leishmaniasis (CL) is a vector-borne tropical neglected disease caused by over 20 different species of kinetoplastid parasites of the genus *Leishmania*. This disfiguring and stigmatizing disease occurs through the injection of promastigote forms into the mammals by infected female sandflies, triggering ulcers and permanent scars at skin and/or oral and nasal mucosa injuries, thus contributing to high social stigmatization and public health issue (WHO, 2020). Although about 1,2 million of new cases occur annually, CL does not have adequate treatment that are mostly based on old and highly toxic drugs besides the occurrence of high number of parasite species with drug resistance profile (Bailey *et al.*, 2019, Alvar *et al.*, 2012, de Vries *et al.*, 2015, Van Bocxlaer *et al.*, 2019).

First line treatments include the clinical use of pentavalent antimonials drugs developed 70 years ago that present several drawbacks in terms of efficacy, safety and require long painful periods of administration (Eiras *et al.*, 2015, DNDi 2018). In the case of antimonial resistance, the second-choice therapy includes pentamidine and amphotericin B (deoxycholate), which also share the previous reported concerns and limitations (Croft 2006, de Vries *et al.*, 2015). Up to now, the only oral and less toxic alternative drug – Milteforan – is unavailable in many developing poorest countries (Bilgic Temel 2019). Besides, the safer liposomal formulation of amphotericin B is highly costly and still under evaluation for effectiveness against CL (Shirzadi 2019).

Last clinical trials for CL were mostly based on drug repurposing and/or combination but unfortunately the overall findings were not very successful to demonstrate an improvement of therapeutic efficacy, such as the combination of Pentavalent antimonial with imiquimoid (Miranda-Verastequi *et al.*, 2009) and the topical use of 3% amphotericin B (Lopez *et al.*, 2018). A phase II clinical trial regarding a shorter course of oral miltefosine administrated in combination with thermotherapy,

77 conducted in Peru and Colombia, ended in 2019 but the outcomes were not published  
78 yet (Valencia *et al.*, 2013, [https://www.dndi.org/diseases-projects/portfolio/new-cl-](https://www.dndi.org/diseases-projects/portfolio/new-cl-combos)  
79 [combos](https://www.dndi.org/diseases-projects/portfolio/new-cl-combos)).

80 Computer aided drug design is an efficient strategy to identify active compounds.  
81 Shape-based screening has been successfully employed for the development of anti-  
82 fungal and anti-bacterial agents (Swinney & Anthony, 2011). To employ this  
83 approach, 3D structure of the target protein/receptor is not required. However, an  
84 established active compound (defined as a query compound) against a target is a  
85 starting point for this approach. The purpose of the shape-based screening is to  
86 identify chemically diverse compounds that show similar biological activity as the  
87 query compound. This is based on the principle that diverse structures that share  
88 similar shape and electrostatic potential surface, or topology will have highest  
89 probability to bind to the same pocket and consequently share the similar activity  
90 (Kumar & Zhang, 2018). Due to the limited information on target proteins of  
91 *Leishmania amazonensis* and the non-availability of quality 3D structures of target  
92 proteins, we have carried out ligand-based shape screening approach using an  
93 established active compound GNF5343 that is reported to display broad spectral anti-  
94 parasitic activity (Khare *et al.*, 2016). We have identified a set of 32 hit compounds  
95 from this study. Thus, the urgent need for safer and selective potent drugs associated  
96 with promising aspects of identified diverse hit compounds encouraged us to perform  
97 *in vitro* phenotypic screening-of these compounds upon amastigotes of *Leishmania*  
98 *amazonensis*, which is one of the main agents of CL in the Americas (Martins 2014,  
99 de Vries *et al.*, 2015).

## Methods

*Compounds:* All 32 identified hit compounds (Chart 1 and Figure 1) that were purchased from Asinex commercial vendor and the reference drug, Pentamidine (Pt), were dissolved in DMSO (stock solutions at 20 mM) and fresh dilutions prepared extemporaneously, with the final concentration never exceeding 0.6% for *in vitro* experiments, which does not induce host cell toxicity (Santos *et al.*, 2019).

*Parasite strain and mammalian host cell cultures:* *Leishmania amazonensis* (strain LTB0016) was used throughout the study. Male BALB/c mice were infected ( $10^6$  amastigotes/20  $\mu$ L culture medium, via subcutaneous) at their foot paws, using a BD ultrafine™ 6 mm syringe (15/64") x 31 G, following previous reported protocol, with minor modifications (Van Bocklaer *et al.*, 2019). After 30 days post infection, the animal skin lesions were aseptically removed, and the parasites obtained by mechanic dissociation (pipetting). The purified amastigotes were then assayed directly with the studied compounds to check the activity upon free amastigote forms (FA), or used to infect primary cultures of peritoneal macrophages (PMM) to investigate their potency against intracellular forms (IA) (Feitosa LM *et al.*, 2019). Swiss male mice (18-20 g) were inoculated with 3% thioglycolate, and after 4 days, PMM collected by rinsing the animals' peritoneum with RPMI 1640. Mammalian cells were seeded at  $24 (3 \times 10^5)$  cells/well) and 96-wells ( $5 \times 10^4$  cells/well) plates and used for *in vitro* infection and host cell cytotoxicity analysis, respectively. The cultures were sustained at 37°C with 5% CO<sub>2</sub> atmosphere in RPMI 1-640 medium (pH 7.2 to 7.4) without phenol red (Gibco BRL) but supplemented with 1% L-glutamine, 1% PEN-STR, 10% fetal bovine serum (FBS). Assays using FA were also maintained at 32°C using the same RPMI culture medium but adding 5% FBS instead of 10%.

*Cytotoxicity upon mammalian host cells and leishmanicidal analysis:* For cytotoxicity analysis, PMM were incubated for 48h with increasing concentrations of the tested compounds (up to 500  $\mu$ M). Cellular viability was evaluated by AlamarBlue tests (Invitrogen) following the manufacturer's instructions (Da Silva *et al.*, 2007, Romanha *et al.*, 2010). The leishmanicidal activity was explored in two steps: in the first set of assays, amastigotes ( $10^6$  parasites per well in 0.2mL) purified from animal lesions (free amastigotes -FA) were exposed for 48 h using a fixed concentration (10  $\mu$ M), and then, drug activity assessed by AlamarBlue tests (Mikus J & Sterverding D, 2000). Then, in a second set of phenotypic screenings, the activity of the compounds was further validated upon intracellular amastigotes (IA). In these assays, PMM ( $3 \times 10^5$ ) were infected with amastigotes ( $9 \times 10^5$  amastigotes) using MOI 3:1 (Van Bocxlaer *et al.*, 2019). After 48 h of compound incubation (0-20  $\mu$ M), infected PMM were rinsed with saline buffered with phosphate (PBS), fixed with Bouin and stained with Giemsa solution for light microscopy analysis (Santos *et al.*, 2019). Then, the percentage of infected host cells and the number of parasites per infected cells were scored for determination of the corresponding infection index (II) that represents the multiplication factor of both parameters. Only characteristic parasite nuclei and kinetoplasts were counted as surviving parasites since irregular structures could mean parasites undergoing death. The results were expressed as % of reduction of the parasite burden and the IC<sub>50</sub> and IC<sub>90</sub> calculated (Santos *et al.*, 2019). All assays were run in at least twice in three independent repeats.

*Compound database preparation:* Using the LigPrep module of the Schrödinger drug design software, a database (Asinex gold) of commercially available compounds was prepared by performing 2D to 3D conversion, addition of hydrogens, generation of ionization states, tautomeric states, stereoisomers and ring conformations at the

physiological pH  $7.0 \pm 2.0$ . Further, energy minimization of all the compounds was carried out using the molecular mechanics OPLS3 force field.

## Results

*Shape-based virtual screening:* Compound GNF5343, an Oxazolo[4,5-b]pyridine derivative (Figure 1) was reported to display activity against *Leishmania donovani*, *Trypanosoma cruzi* and *Trypanosoma brucei* (Khare *et al.*, 2016). This compound was used as a query compound to perform the virtual screening of a set of 60,000 chemically diverse compounds from the Asinex database. These compounds were selected by applying the Lipinski filter ( $\text{Mol.Wt} \leq 500$ ;  $\text{cLogP} \leq 5$ ;  $\text{HBA} \leq 10$ ;  $\text{HBD} \leq 5$ ), removing the compounds with nitro groups and reactive functional groups (QikProp, Schrödinger release 2017-2). Using the shape-based virtual screening approach, each conformer of the molecule from the database was aligned to the query compound and phase sim score was computed based on the maximum overlapping characteristics. Compounds with shape sim score between 0.85 to 0.6 were visually inspected to assess the structural diversity and synthetic accessibility. Based on these criteria, a subset of 31 compounds (Chart 1) was selected and Hierarchical clustering was performed, in which 2D fingerprints and atom pairs were used as metrics to quantify the chemical diversity (Canvas, Schrödinger release 2017-2). A total of 11 clusters were identified, of which five were singletons with diverse chemical structures such as Quinoxaline derivative (cluster 4), Imidazo[2,1-b]thiazole derivative (cluster 6), benzoxazole derivative (cluster 9), 2-oxo-2H-chromene derivative (cluster 10) and 3-imidazo[1,2-a] pyridine derivative (cluster 11). As the query compound GNF5343 was not available for purchase, we have selected one of its close analogue Cp1 (Figure 1) for the comparative studies along with the selected set of 31 hit compounds. Cp1 differs from GNF5343 in having a thiophenyl ring

substitution instead of furyl ring. All 32 compounds were purchased from Asinex and assayed using different protocols *in vitro*. A fixed concentration (10  $\mu$ M) was first assessed on free amastigotes (FA) and findings demonstrated that two (Cp1 and Cp2) out of the 32 compounds reduced ( $\geq 50$  %) the number of live parasites. Analogues of Cp2 from cluster 1 (Chart 1: 2a and 2b) displayed weak inhibition. Compounds from other clusters did not show any activity. While Cp1 is a close analogue of query compound, Cp2 is structurally diverse from GNF5343 in having benzimidazole scaffold. Both GNF5343 and Cp2 displayed good alignment and maximum volume overlap (Figure 1) indicating that these two compounds are having similar topology to form similar van der Waals surface interactions at the same region. It is interesting to notice the varied distribution of hydrogen bond donors (HBD), hydrogen bond acceptors (HBA) and hydrophobicity between the basic scaffolds (Oxazolo[4,5-b]pyridine Vs benzimidazole) of GNF5343 and Cp2. These active compounds (Cp1 and Cp2) and the reference drug Pentamidine (Pt) were further analyzed against FA using increasing concentrations of the tested compounds and Pt. The findings showed moderate leishmanicidal effect, with IC<sub>50</sub> values of 14.93 and 15.86  $\mu$ M for Cp1 and Cp2 respectively, being less potent than Pt (0.71  $\mu$ M) (Table 1). In the second round of assays, the compounds were further evaluated against intracellular amastigotes present in the cytoplasm of PPM, which represent the gold models for *in vitro* screening of leishmanicidal agents (DNDi, 2018). Our data showed that both compounds were active upon IA, exhibiting IC<sub>50</sub> values of 7 and 8.50  $\mu$ M, respectively, while Pt gave 1.94  $\mu$ M (Table 1). Against the IA, Cp1 and Cp2 reached low IC<sub>90</sub> values (17.25  $\pm$  0.21  $\mu$ M and 18.54 $\pm$ 0.96  $\mu$ M), exhibiting a leishmanicidal profile since both drastically dropped the number of parasites per cells as well as the percentage of infected PMM (Figure 2). Regarding the mammalian host cell toxicity,



we found that after 48 h of exposure, Cp1 and Cp2 were about 3-fold less toxic as compared to Pt, giving  $IC_{50}$  of  $62.75 \pm 0.27$  and  $65.39 \pm 0.61$ , with selectivity indexes of 6 and 9, respectively, in similar range than the reference drug (SI = 8, Table 1).

*In silico* assessment of drug likeness and DMPK properties is most effective way in reducing time, expenses and maximize the success in drug discovery process (Lombardo *et al.*, 2017). Therefore, drug likeness and DMPK properties were predicted for both Cp1 and Cp2 using the QikProp module (QikProp, Schrödinger release 2017-2). Recommended compliance scores are given in Table 2. The predicted properties of Cp1 and Cp2 showed compliance with “Lipinski rule of five”. According to “Jorgensen rule of three” any compound that meet the recommended criteria (Table 2) are more likely to be orally available. The predicted properties of both Cp1 and Cp2 displayed compliance with “Jorgensen rule of three”. Hence these compounds could show good permeability and solubility properties. Both these properties are crucial for good oral bioavailability. QPPMDCK values are the prediction of MDCK cell permeability (nm/s) which is a good mimic for blood brain permeation. According to this, both compounds displayed good blood brain permeation. The efficiency of a drug may be affected by the extent at which it binds to human plasma protein. If compounds show high binding affinity to serum albumin this could lead to poor efficacy. Hence it is very crucial to understand the binding characteristics of Cp1 and Cp2. The predicted human serum albumin binding values (Table 2) for both Cp1 and Cp2 are within the permissible range indicating a lower binding affinity to the serum albumin protein.

## Discussion

The entire process of drug discovery is extremely costly and takes at least one decade of pre-clinical and clinical studies: 1 out of 10,000 drug candidates succeeds in this long flowchart, and finally reaches successfully into the market (Van Norman 2016). In this context, more reliable and reproducible experimental models (*in vitro* and *in vivo*) are needed to find better translation among pre-clinical and clinical outcomes of novel antiparasitic drugs (Chatelain & Konar 2015, Katsuno 2015). Presently, our analysis was performed using primary cultures of peritoneal macrophages infected with *L. amazonensis* since professional phagocytes are the main source of host cells for those obligate intracellular parasites (Walker *et al.*, 2015). This *in vitro* standardized experimental model for CL is claimed to closely reproduce *in vivo* conditions (Stacey 2006), therefore contributing to novel drug candidate screenings for this neglected illness (Chatelain & Ioset 2011, Caridha *et al.*, 2019). Also, although in Asia and Africa continents CL is mainly caused by *L. major* and *L. tropica*; in the Americas, the disease is triggered by a higher number of species including *L. amazonensis*, justifying the present use of this parasite species (Martins 2014, de Vries *et al.*, 2015). *L. amazonensis* is a relevant species in Brazil closely related to a wide spectrum of CL pathologies, including highly severe diffuse cutaneous leishmaniasis (Lainson, 1994). These data corroborate the choice of our *in vitro* model to explore the potential effect of novel anti-CL compounds. Another interesting point to be addressed is the use of protocols that enable the identification of antiparasitic drugs that induces rapid parasite lysis (Da Silva *et al.*, 2011). This is especial characteristic as most of the CL patients live in very poor areas with difficult access to public health assistance and then, frequently display advanced pathologies, demanding a fast *killer* drug (Ruoti *et al.*, 2013, Okwor & Uzonna 2016). Aiming to

fulfill this demand, we established a period of 48 h of drug exposure while testing the parasites and host mammalian cells, a shorter period of incubation as compared others reported in the current literature for CL *in vitro* models (Van Bocklaer, 2019).

Our present study explored the leishmanicidal effect of Cp1 (an analogue of GNF5343) and Cp2 (a benzimidazole analogue) identified using shape-based virtual screening approach. Both Cp1 and Cp2 achieved quite relevant potency against amastigotes, especially those lodge inside macrophages, reaching IC<sub>50</sub> values below 10 µM, a considerable characteristic preconized for a hit compound with anti-leishmania effect (Katsuno, 2015). Remarkably, clearance on *L. amazonensis* infection was found at 20 µM in the infected PMM, a relevant feature to mitigate the possible occurrence of parasite drug resistance and relapses after ceasing the drug administration (Cal *et al.*, 2016). The Cp1 and Cp2 were less toxic than the reference drug (pentamidine) still in use for Leishmaniasis but their selectivity indexes (>10) discouraged to move them for *in vivo* proof of concept. However, their chemical optimization for a wider therapeutic window and promotion of potency is largely desirable to continue further studies using these compounds. It is also important to state that the first-line drug pentamidine – used to treat the first stage of Sleeping Sickness and CL-caused by *L. guyanensis* by over seven decades – also doesn't have a desirable selectiveness *in vitro* due to high toxic profile, although display an outstanding potency against these parasites. Currently, we are performing structural modifications of Cp2 aiming to improve its potency, selectivity and satisfactory pharmacological profile, favoring future phenotypic studies in order to move its derivatives forward to new *in vitro* screening and *in vivo* evaluation, aiming to contribute for drug discovery process of new therapeutic approaches for cutaneous

leishmaniasis. These analogues will also be tested against other parasites to assess their broad-spectrum antiparasitic activity.

## FINANCIAL SUPPORT

The present study was supported by grants from Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ), Conselho Nacional Desenvolvimento científico e Tecnológico (CNPq), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), and Fundação Oswaldo Cruz, PDTIS, PAEF/CNPq/Fiocruz. MNCS is research fellows of CNPq and CNE researchers.

## ACKNOWLEDGMENTS

The authors thank the Fortalecimento dos Programas de Gestão Estratégica de Pesquisa da Fiocruz Rede de Plataformas Fiocruz (VPPLR - 001 - Fio 14) and the Programa de Excelência Acadêmica (PROEX) from CAPES.

## REFERENCES

- Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, *et al.***, (2012) Leishmaniasis Worldwide and Global Estimates of Its Incidence. PLoS ONE 7(5): e35671., v. 7, p. 1-12 doi:10.1371/journal.pone.0035671.
- Bailey F, Mondragon-Shem K, Haines LR, Olabi A, Alorfi A, Ruiz-Postigo JA, *et al.***, (2019) Cutaneous leishmaniasis and co-morbid major depressive disorder: A systematic review with burden estimates.

**Barrett MP, Boykin DW, Brun R, & Tidwell RR.** (2007). Human African trypanosomiasis: pharmacological re-engagement with a neglected disease. *British journal of pharmacology*, 152(8), 1155–1171. <https://doi.org/10.1038/sj.bjp.0707354>

**Bilgic-Temel A, Murrell, DF, & Uzun S** (2019). Cutaneous leishmaniasis: A neglected disfiguring disease for women. *International journal of women's dermatology*, 5(3), 158–165. <https://doi.org/10.1016/j.ijwd.2019.01.002>

**Canvas, Schrödinger** Release 2017-2: Maestro, Schrödinger, LLC, New York, NY, 2017.

**Caridha D, Vesely B, van Bocxlaer K, Arana B, Mowbray CE, Rafati S, Uliana S, Reguera R, Kreishman-Deitrick M, Sciotti R, Buffet P, Croft SL** (2019) Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis. *Int J Parasitol Drugs Drug Resist*. 2019 Dec;11:106-117. doi: 10.1016/j.ijpddr.2019.06.003. PMID: 31320296; PMCID: PMC6904839.

**Chatelain E, Ioset JR** (2011) Drug discovery and development for neglected diseases: the DNDi model. *Drug Des Devel Ther* 16;5:175-81. doi: 10.2147/DDDT.S16381. PMID: 21552487; PMCID: PMC3084299.

**Chatelain E, Konar N** (2015) Translational challenges of animal models in Chagas disease drug development: a review. *Drug Des Devel Ther* 9:4807– 4823. <https://doi.org/10.2147/DDDT.S90208>.

**Cal M, Ioset J-R, Fügi MA, Mäser P, Kaiser M.** (2016) Assessing anti-*T. cruzi* candidates in vitro for sterile cidalty. *Int J Parasitol Drugs Drug Resist* 6:165–170. <https://doi.org/10.1016/j.ijpddr.2016.08.003>.

**Croft SL, Sundar S & Fairlamb AH** (2006). Drug resistance in leishmaniasis. *Clinical microbiology reviews*, 19(1), 111–126. DOI: 10.1128/CMR.19.1.111-126.2006

**Da Silva CF, Batista MM, Mota RA, de Souza EM, Stephens CE, Som P, Boykin DW, Soeiro Mde N** (2007) Activity of "reversed" diamidines against *Trypanosoma cruzi* "in vitro". *Biochem Pharmacol.* 2007 Jun 15;73 (12):1939-46

**de Vries HJ, Reedijk SH, Schallig HD** (2015) Cutaneous leishmaniasis: recent developments in diagnosis and management. *Am J Clin Dermatol.* Apr;16(2):99-109.

**DNDi Annual report** (2018). Making medical history. 08/03/2020 [https://www.dndi.org/wp-content/uploads/2019/07/DNDi\\_2018\\_AnnualReport.pdf](https://www.dndi.org/wp-content/uploads/2019/07/DNDi_2018_AnnualReport.pdf)

**Feitosa LM, da Silva ER, Hoelz LVB, Souza DL, Come JAASS, Cardoso-Santos C, Batista MM, Soeiro MNC, Boechat N, Pinheiro LCS** (2019) New pyrazolopyrimidine derivatives as *Leishmania amazonensis* arginase inhibitors. *Bioorg Med Chem.* 15;27(14):3061-3069. doi: 10.1016/j.bmc.2019.05.026.

**Eiras DP, Kirkman LA & Murray HW** (2015) Cutaneous Leishmaniasis: Current Treatment Practices in the USA for Returning Travelers. *Curr Treat Options Infect Dis.* Mar 1;7(1):52-62. doi: 10.1007/s40506-015-0038-4. PMID: 25788870; PMCID: PMC4360962.

**Godinho JL, Simas-Rodrigues C, Silva R, Ürmenyi TP, de Souza W, Rodrigues JC** (2012) Efficacy of miltefosine treatment in *Leishmania amazonensis*-infected BALB/c mice. *Int J Antimicrob Agents.* 39(4):326-31. doi: 10.1016/j.ijantimicag.2011.11.008. Epub 2012 Jan 9.

**Katsuno K, Burrows JN, Duncan K, Hooft van Huijsduijnen R, Kaneko T.** (2015) Hit and lead criteria in drug discovery for infectious diseases of the developing world. *Nature Reviews Drug Discovery* 14:751–758.

**Khare S, Nagle AS, Biggart A, Lai YH, , Liang F, Davis LC, Barnesn, SW, Mathison CJN, Myburgh E, Gao, MY, Gillespie, JR, Liu X, Tan, JL, Stinson M,**

**Rivera, IC, , Ballard J, Yeh V, Groessl T, Federe G, Koh, HXY, Venable JD, Bursulaya, B, Shapiro M, Mishra PK, Spraggon G, Brock A, Mottram JC, Buckner FS, Rao SPS, Wen BG, Walker JR, Tuntland T, Molteni V, Glynne RJ, and Supek F. (2016) Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness. Nature. 537(7619): 229–233. doi:10.1038/nature19339.**

**Kumar A, Zhang KYJ. (2018) Advances in the Development of Shape Similarity Methods and Their Application in Drug Discovery. Front. Chem. 6:315. doi: 10.3389/fchem.2018.00315.**

**Lainson R, Shaw JJ, Silveira FT, de Souza AAA, Braga RR, Ishikawa EAY (1994) The dermal leishmaniasis of Brazil, with special reference to the eco-epidemiology of the disease in Amazonia. Mem Inst Oswaldo Cruz. 89:435–43.**

**Lombardo F, Desai PV, Arimoto R, Desino KE, Fischer H, Keefer CE, Petersson C, Winiwarter S, and Broccatelli F. (2017) In Silico Absorption, Distribution, Metabolism, Excretion, and Pharmacokinetics (ADME-PK): Utility and Best Practices. An Industry Perspective from the International Consortium for Innovation through Quality in Pharmaceutical Development. J. Med. Chem. 60, 9097-9113.**

**López L, Vélez I, Asela C, Cruz C, Alves F, Robledo S, Arana B. (2018) A phase II study to evaluate the safety and efficacy of topical 3% amphotericin B cream (Anfoleish) for the treatment of uncomplicated cutaneous leishmaniasis in Colombia.**

PLoS neglected tropical diseases, 12(7), e0006653.  
<https://doi.org/10.1371/journal.pntd.0006653>

**Martins AL, Barreto JA, Lauris JR, Martins AC** (2014) American tegumentary leishmaniasis: correlations among immunological, histopathological and clinical parameters. *An Bras Dermatol.* Jan-Feb;89(1):52-8.

**Mikus J & Sterverding D** (2000) A simple colorimetric to screen drug cytotoxicity against *Leishmania* using the dyaAlamar blue. [Parasitol Int.](#) Jan;48(3):265-9.

**Miranda-Verastegui C, Tulliano G, Gyorkos TW, Calderon W, Rahme E, et al.** (2009) First-Line Therapy for Human Cutaneous Leishmaniasis in Peru Using the TLR7 Agonist Imiquimod in Combination with Pentavalent Antimony. *PLoS Negl Trop Dis* 3(7): e491. doi:10.1371/journal.pntd.0000491

QikProp, virtual screening workflow, Schrödinger Release 2017-2: Maestro, Schrödinger, LLC, New York, NY, 2017.

**Okwor I & Uzonna J** (2016) Social and Economic Burden of Human Leishmaniasis. *Am J Trop Med Hyg.* 2016;94(3):489–493.

**Romanha AJ, Castro SL, Soeiro Mde N, Lannes-Vieira J, Ribeiro I, Talvani A, Bourdin B, Blum B, Olivieri B, Zani C, Spadafora C, Chiari E, Chatelain E, Chaves G, Calzada JE, Bustamante JM, Freitas-Junior LH, Romero LI, Bahia MT, Lotrowska M, Soares M, Andrade SG, Armstrong T, Degraive W, Andrade Zde A** (2010) *In vitro* and *in vivo* experimental models for drug screening and development for Chagas disease. *Mem Inst Oswaldo Cr uz.* 105(2):233-8

**Ruoti M, Oddone R, Lampert N, Orué E, Miles MA, Alexander N, Rehman AM, Njord R, Shu S, Brice S, Sinclair B, Krentel A.** (2013) Mucocutaneous



leishmaniasis: knowledge, attitudes, and practices among paraguayan communities, patients, and health professionals. J Trop Med.

**Santos CC, Lionel JR, Peres RB, Batista MM, da Silva PB, de Oliveira GM, da Silva CF, Batista D, Souza S, Andrade CH, Neves BJ, Braga RC, Patrick DA, Bakunova SM, Tidwell RR, Soeiro M.** (2018) *In Vitro, In Silico, and In Vivo* Analyses of Novel Aromatic Amidines against *Trypanosoma cruzi*. *Antimicrobial agents and chemotherapy*, 62(2), e02205-17. doi:10.1128/AAC.02205-17

**Shirzadi MR** (2019) Liposomal amphotericin B: a review of its properties, function, and use for treatment of cutaneous leishmaniasis. *Research and reports in tropical medicine*, 10, 11–18. <https://doi.org/10.2147/RRTM.S200218>

**Stacey, G.** (2006) Primary Cell Cultures and Immortal Cell Lines. *Encyclopedia of Life Sciences*. doi:10.1038/npg.els.0003960

**Swinney, DC & Anthony J** (2011). How were new medicines discovered? *Nat. Rev. Drug Discov.* 10(7), 507-519. doi: 10.1038/nrd3480.


**Valencia BM, Miller D, Witzig RS, Boggild AK, Llanos-Cuentas A** (2013) Novel Low-Cost Thermo-therapy for Cutaneous Leishmaniasis in Peru. *PLoS Negl Trop Dis* 7(5): e2196. doi:10.1371/journal.pntd.0002196

**Van Bocxlaer K, Caridha D, Black C, Vesely B, Leed S, Sciotti RJ, Wijnant GJ, Yardley V, Braillard S, Mowbray CE, Ioset JR, Croft SL** (2019) Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis. *Int J Parasitol Drugs Drug Resist.* v11:129–138. doi:10.1016/j.ijpddr.2019.02.002

**Van Norman GA** (2016) Drugs, Devices, and the FDA: Part 1: An Overview of Approval Processes for Drugs. JACC.V1(3),170-179. DOI:10.1016/j.jacbts.2016.03.002


**Walker DM, Oghumu S, Gupta G, McGwire BS, Drew ME, Satoskar AR.** Mechanisms of cellular invasion by intracellular parasites (2014) Cell Mol Life Sci. Apr;71(7):1245-63. doi: 10.1007/s00018-013-1491-1. Epub 2013 Nov 13. PMID: 24221133; PMCID: PMC4107162.


**World Health Organization** (2020) Leishmaniasis factsheet — 2015(*last update 2 Mar. 2020*) Brazil. Retrieved from <https://www.who.int/en/news-room/factsheets/detail/leishmaniasis> Mar 8, 2020<sup>th</sup>.



**Figure 1.** Shape-based virtual screening results. a) Illustrating the good alignment of query compound GNF5343 (orange sticks) with compound **2** (atom type coloured sticks). b) Displaying maximum volume overlap that indicates good shape complementarity between the query compound (represented with mesh with an area of 300 Å<sup>2</sup>) and the compound **2** (represented with van der Waals molecular surface area of 326.5 Å<sup>2</sup>). c) Molecular structures and their associated activity data. 1a & 1b Images are generated using Phase-Schrödinger drug design software. (Reddy, please correct “brucei” in figure 1c)

**Chart 1.** Clusters of hit compounds identified by shape-based virtual screening strategy





**Figure 2.** Light microscopy images of Giemsa-stained uninfected and infected PMM submitted or not (untreated) to 10 and 20  $\mu$ M of Cp1 and Cp2, demonstrating parasite sterilization at 20  $\mu$ M. Arrows: intracellular parasites.

**Table 1.** The leishmanicidal activity and cytotoxicity effect (IC<sub>50</sub> - mean and SD) on peritoneal macrophage (PMM) of Cp1 and Cp2. The compounds were tested (48 hours of incubation) upon amastigote forms purified from mice lesions (FA) and on intracellular amastigote forms (IA) hosted in PMM. SI: selective indexes.

Compound	IC <sub>50</sub> (μM) <sub>PMM</sub>	IC <sub>50</sub> (μM) <sub>FA</sub>	IC <sub>50</sub> (μM) <sub>IA</sub>	SI <sub>FA</sub>	SI <sub>IA</sub>
Cp 1	62.75±0.27	13.03±2.69	9.35±1.87	4.82	6.71
Cp 2	65.39±0.61	14.09±2.24	7.25±1.46	4.64	9.02
Pentamidine	15.88±0.59	0.71±0.05	1.94±0.50	22.37	8.19

**Table 2.** *In-silico* assessment of drug likeness and DMPK properties of Cp1 and Cp2

		Recommended compliance score (range for 95% of drugs)	Compound ID	
			Cp1	Cp2
Lipinski Rule of five	Mol.Wt	≤ 500	355.80	365.794
	HBD	≤ 5	1	2
	HBA	≤ 10	4	2
	cLogP	≤5	3.36	4.59
Jorgensen Rule of three	QPlogS	-6.5 to 0.5	-5.380	-6.289
	QPCaco	<25 poor, >500 great	1403	1721
	Primary metabolites	<7	3	0
% Human oral absorption	-	>80% is high, <25% is low	100	100
QPPMDCK	-	>500 great, <25 poor	2650	3285
QPlogKhsa	-	-1.5 to 1.5	0.243	0.616

Mol.Wt: Molecular Weight; HBD: hydrogen bond donor; HBA: hydrogen bond acceptor; cLogP: calculated logarithm of partition coefficient; QPlogS: the logarithm of aqueous solubility; QPCaco: Caco-2 cell permeability in nm/sec, model for the gut-blood barrier; QPPMDCK: Madin-Darby canine kidney (MDCK) cell permeability in nm/sec, model for the blood-brain barrier; QPlogKhsa: the logarithm of predicted binding constant to human serum albumin.